Defence Therapeutics Inc. (DTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Defence Therapeutics Inc. (DTC) has a cash flow conversion efficiency ratio of 1.144x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.40 Million ≈ $-1.64 Million USD) by net assets (€-1.22 Million ≈ $-1.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DTC company net worth for the company's overall valuation and market capitalisation.
Defence Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Defence Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Defence Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Defence Therapeutics Inc. ranked by their cash flow conversion efficiency. See DTC debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Primega Group Holdings Limited Ordinary Shares
NASDAQ:PGHL
|
N/A |
|
Yellow Cake PLC
LSE:YCA
|
-0.004x |
|
New Bubbleroom Sweden AB
ST:BBROOM
|
0.097x |
|
Primech Holdings Ltd. Ordinary Shares
NASDAQ:PMEC
|
0.218x |
|
Anoto Group AB
ST:ANOT
|
0.251x |
|
Samyang Holdings Corp
KO:000075
|
0.036x |
|
Inzi Display Co.Ltd
KQ:037330
|
0.157x |
|
Southern Hemisphere Mining Ltd
AU:SUH
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Defence Therapeutics Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Defence Therapeutics Inc. from 2020 to 2024. View Defence Therapeutics Inc. stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | €-3.58 Million ≈ $-4.19 Million |
€-4.29 Million ≈ $-5.01 Million |
1.196x | +124.47% |
| 2023-06-30 | €1.57 Million ≈ $1.83 Million |
€-7.66 Million ≈ $-8.95 Million |
-4.889x | -131.35% |
| 2022-06-30 | €-387.56K ≈ $-453.10K |
€-6.04 Million ≈ $-7.07 Million |
15.596x | +3837.50% |
| 2021-06-30 | €5.49 Million ≈ $6.41 Million |
€-2.29 Million ≈ $-2.68 Million |
-0.417x | -485.46% |
| 2020-06-30 | €1.86 Million ≈ $2.18 Million |
€-132.83K ≈ $-155.29K |
-0.071x | -- |
About Defence Therapeutics Inc.
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting vario… Read more